The Series D funding will support manufacturing, commercial deployment, and continued development of the company’s upright platform for proton therapy, photon therapy, and imaging.
Leo Cancer Care announced it has closed a $65 million Series D financing round to support manufacturing, commercial deployment, and continued clinical and product development of its upright cancer care platform.
The financing will scale manufacturing and accelerate commercial deployment, and continue clinical and product development across Leo Cancer Care’s integrated upright platform—spanning proton therapy, photon therapy, and imaging. The same upright architecture is applied across all three.
The financing follows the first clinical use of the company’s Marie upright proton therapy platform at Stanford Medicine, where clinicians delivered what the company says was the world’s first compact upright proton therapy treatment in June 2026.
Leo Cancer Care says its platform is designed around imaging and treating patients in an upright position rather than lying down. The company cites research suggesting upright positioning may support more consistent anatomical positioning and organ stability than conventional supine treatment.
The company’s upright imaging system has received US Food and Drug Administration clearance and is intended for treatment planning and delivery, with future radiology applications planned, according to the release.
The Marie platform rotates a seated patient while keeping the radiation beam fixed rather than rotating a gantry. According to the company, this design allows proton therapy systems to fit into smaller treatment rooms than conventional gantry-based systems.
Leo Cancer Care also announced it has entered into a strategic partnership with an international healthcare company. Additional details are expected to be announced separately.
